Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review

Published:2022-10-28 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Sheth Hardik,Limaye Sewanti,Kumar Prashant,Shreenivas Aditya

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04428-w.pdf

Reference34 articles.

1. Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21(5):671–684. https://doi.org/10.1016/S1470-2045(20)30109-1

2. Ahn DH, Bekaii-Saab T (2017) Biliary cancer: intrahepatic cholangiocarcinoma vs extrahepatic cholangiocarcinoma vs gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol 8:293–301

3. Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T et al (2020) FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol 16(30):2385–2399. https://doi.org/10.2217/fon-2020-0429 (Epub 2020 Jul 17)

4. Cristinziano G, Porru M, Lamberti D, Buglioni S, Rollo F, Amoreo CA et al (2021) FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. J Hepatol 75(2):351–362. https://doi.org/10.1016/j.jhep.2021.02.032 (Epub 2021 Mar 17 PMID: 33741397)

5. Dienstmann R, Rodon J, Prat A et al (2014) Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol 25(3):552–563. https://doi.org/10.1093/annonc/mdt419

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2024-03-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3